Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

NCT03971409 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

145

Enrollment

OTHER

Sponsor class

Conditions

Stage III Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Invasive Breast Carcinoma
Recurrent Breast Carcinoma
Triple-Negative Breast Carcinoma
Unresectable Breast Carcinoma

Interventions

BIOLOGICAL: Anti-OX40 Antibody PF-04518600
DRUG: Avelumab
DRUG: Binimetinib
BIOLOGICAL: Utomilumab
DRUG: Liposomal Doxorubicin
DRUG: Sacituzumab Govitecan

Sponsor

Laura Huppert, MD, BA

Collaborators

Translational Breast Cancer Research Consortium
Hoosier Cancer Research Network
Array BioPharma
Pfizer
Breast Cancer Research Foundation
Johns Hopkins University
Gilead Sciences